Sequential Skin, a global leader in skin microbiome testing, and AMILI, a leading expert in gut microbiome science, have been awarded the prestigious UK-Singapore Collaborative R&D Grant. This $1.8 million project, supported by Innovate UK and Enterprise SG, will fund groundbreaking research into the interplay between the skin and gut microbiomes, offering new insights into the evaluation and treatment of inflammatory skin disorders (ISDs) such as atopic dermatitis and psoriasis.
Sequential, with its extensive database of over 25,000 clinical skin microbiome samples and pioneering at-home skin microbiome tests, has established itself as a leader in the field. The company collaborates with over 80 personal care and pharmaceutical companies, driving innovation in skin microbiome research and development.
AMILI, headquartered in Singapore, is a renowned leader in gut microbiome research. Since 2014, AMILI has been at the forefront of this field, conducting pioneering research and developing Asia’s largest multi-ethnic gut microbiome database. This extensive database enables AMILI to map the complex relationships and mechanistic pathways between changes in the gut microbiome and various health conditions.
This collaborative research effort will leverage the expertise of both companies, combining Sequential’s deep understanding of the skin microbiome with AMILI’s expertise in gut microbiome research. The project aims to unlock new avenues for developing targeted, microbiome-driven interventions for the treatment of inflammatory skin disorders.
